Prediction Case File
YouTubeEvaluation Complete

Novo Nordisk and UnitedHealth have seen their share prices fall in recent weeks.

1 extracted signal · 1 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
13 Aug 2025, 19:45 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Novo Nordisk and UnitedHealth have seen their share prices fall in recent weeks.
Source overview

AI-generated source summary

The analysis compares Novo Nordisk (NOVOb) and UnitedHealth (UNH), both near 52-week lows. Revenue growth, profit margins, and returns on invested capital were analyzed. For Novo Nordisk the intrinsic value is estimated around $127.47 with the current price at $49.87. United Health's intrinsic value is estimated at $434, significantly above its market price of $252.37. Revenue growth is expected to be better for NOVO than UNH, operating margin is 47.7% and improving for NOVO, and WACC is 8.14%. However, Novo faces competition from Eli Lilly and compounded medications. UNH faces customer loss due to pricing and market exits, their OC to WACC ratio is below 1.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
1
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
100%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail